Pegcetacoplan

(Empaveli)

Pegcetacoplan

Drug updated on 11/14/2023

Dosage FormInjection (subcutaneous; 1,080 mg/20 mL (54 mg/mL))
Drug ClassComplement inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Product Monograph / Prescribing Information

Document TitleYearSource
Empaveli (pegcetacoplan) Prescribing Information.2023Apellis Pharmaceuticals, Inc., Waltham, MA

Systematic Reviews / Meta-Analyses